Quoin Pharmaceuticals Ltd ADR (QNRX)

$8.80 -0.39 (-4.24%)
Market Cap 5.18M
Revenue (ttm) 0.00
Net Income (ttm) -8.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,700
Avg Vol 221,644
Day's Range N/A - N/A
Shares Out 588,000.00
Stochastic %K 41%
Beta 1.47
Analysts Strong Sell
Price Target $50.00

Company Profile

Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queens...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 980 4182
Address:
42127 Pleasant Forest Court, Ashburn, United States
GreenResearchers
GreenResearchers Jul. 7 at 4:01 AM
Good luck traders I like the stocks tagged and keep an eye on SSY , small caps are HOT SSY is a textbook low-float sleeper with a catalyst. No dilution. Micro float. Merger with Regional Health is still in motion and the market’s ignoring it. These are the types of plays that go from dead quiet to 300%+ in a blink. You either see it early or chase it late. $GNS $IFBD $TIRX $QNRX
0 · Reply
GreenResearchers
GreenResearchers Jul. 5 at 8:31 PM
SSY is being slept on. Tiny float. No dilution. Under $1. There’s a major merger in the works and barely anyone’s watching. When these setups move, they don’t walk they rip. The chart is coiled, and all it needs is volume. $IFBD $QNRX $APRN $VEEE
0 · Reply
rockytoday
rockytoday Jul. 3 at 4:39 PM
$QNRX buy the dip
0 · Reply
magic2007
magic2007 Jul. 3 at 2:23 PM
$QNRX So I invested 7k way back, and now I see I have 14 shares. Wow, I guess I ride it out..
1 · Reply
CashMoneyGlitch
CashMoneyGlitch Jun. 30 at 8:54 PM
Can we see a massive run of SQFT into close? Stay tuned bulls! SQFT has only 500k shares outstanding! Momentum breakout on SQFT now! Don't miss out! Could be the next 300% low float mania gapper! $ILLR $BTC.X $KITT $QNRX About to run !
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 5:34 PM
$QNRX 20k shares available borrow free 49 percent at
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 3:09 PM
$CYN watch $QNRX this is also next
0 · Reply
prismmarketview
prismmarketview Jun. 26 at 2:37 PM
$QNRX “It’s not just a skin disease—it can be life-threatening.” Quoin Pharmaceuticals (Nasdaq: QNRX) spotlights the urgent pediatric need in Netherton Syndrome in a powerful new NETHERTON NOW episode featuring leading dermatologist Prof. Jemima Mellerio. Don’t miss this expert perspective on the fight to bring treatments to children who need them mosthttps://prismmarketview.com/quoin-pharmaceuticals-highlights-urgent-pediatric-need-in-netherton-syndrome-with-new-expert-video/
0 · Reply
StayPresent
StayPresent Jun. 25 at 11:18 PM
$QNRX should be OTC. China dog💩
1 · Reply
Yuyus
Yuyus Jun. 25 at 11:36 AM
$QNRX Quoin Pharmaceuticals Secures FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome June 24, 2025
0 · Reply
Latest News on QNRX
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 20, 2025, 7:30 AM EDT - 6 weeks ago

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

May 14, 2025, 7:30 AM EDT - 7 weeks ago

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Apr 30, 2025, 7:30 AM EDT - 2 months ago

Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Apr 10, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Apr 2, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Mar 31, 2025, 4:18 AM EDT - 3 months ago

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 25, 2025, 7:30 AM EDT - 3 months ago

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 13, 2025, 7:30 AM EDT - 4 months ago

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Mar 4, 2025, 7:30 AM EST - 4 months ago

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Feb 27, 2025, 7:30 AM EST - 4 months ago

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Feb 25, 2025, 7:30 AM EST - 4 months ago

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Feb 4, 2025, 7:30 AM EST - 5 months ago

Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Jan 23, 2025, 8:30 AM EST - 5 months ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 23, 2025, 5:30 AM EST - 5 months ago

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Jan 6, 2025, 8:30 AM EST - 6 months ago

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Dec 20, 2024, 9:20 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Dec 19, 2024, 8:00 AM EST - 7 months ago

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Dec 18, 2024, 8:18 AM EST - 7 months ago

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Oct 31, 2024, 4:05 PM EDT - 8 months ago

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Sep 9, 2024, 8:30 AM EDT - 10 months ago

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 8:30 AM EDT - 11 months ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Aug 6, 2024, 5:00 AM EDT - 11 months ago

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Aug 1, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Jun 25, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 9, 2024, 8:30 AM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

May 2, 2024, 4:10 PM EDT - 1 year ago

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 12:57 PM EDT - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Mar 7, 2024, 4:05 PM EST - 1 year ago

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Feb 14, 2024, 9:00 AM EST - 1 year ago

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Dec 13, 2023, 8:30 AM EST - 1 year ago

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 10:51 AM EST - 1 year ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 8, 2023, 5:46 PM EST - 1 year ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

Nov 3, 2023, 8:41 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 9:32 AM EDT - 1 year ago

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Oct 24, 2023, 8:28 AM EDT - 1 year ago

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 1:24 AM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

Aug 2, 2023, 4:45 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

May 24, 2023, 8:15 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Call Transcript

May 12, 2023, 4:43 PM EDT - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

May 8, 2023, 5:00 PM EDT - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

May 2, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Mar 21, 2023, 8:30 AM EDT - 2 years ago

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Call Transcript

Mar 9, 2023, 2:27 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Call Transcript

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 8, 2023, 5:08 PM EST - 2 years ago

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Mar 2, 2023, 4:05 PM EST - 2 years ago

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Feb 22, 2023, 8:39 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Dec 13, 2022, 8:30 AM EST - 2 years ago

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 2:38 PM EST - 2 years ago

Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript

GreenResearchers
GreenResearchers Jul. 7 at 4:01 AM
Good luck traders I like the stocks tagged and keep an eye on SSY , small caps are HOT SSY is a textbook low-float sleeper with a catalyst. No dilution. Micro float. Merger with Regional Health is still in motion and the market’s ignoring it. These are the types of plays that go from dead quiet to 300%+ in a blink. You either see it early or chase it late. $GNS $IFBD $TIRX $QNRX
0 · Reply
GreenResearchers
GreenResearchers Jul. 5 at 8:31 PM
SSY is being slept on. Tiny float. No dilution. Under $1. There’s a major merger in the works and barely anyone’s watching. When these setups move, they don’t walk they rip. The chart is coiled, and all it needs is volume. $IFBD $QNRX $APRN $VEEE
0 · Reply
rockytoday
rockytoday Jul. 3 at 4:39 PM
$QNRX buy the dip
0 · Reply
magic2007
magic2007 Jul. 3 at 2:23 PM
$QNRX So I invested 7k way back, and now I see I have 14 shares. Wow, I guess I ride it out..
1 · Reply
CashMoneyGlitch
CashMoneyGlitch Jun. 30 at 8:54 PM
Can we see a massive run of SQFT into close? Stay tuned bulls! SQFT has only 500k shares outstanding! Momentum breakout on SQFT now! Don't miss out! Could be the next 300% low float mania gapper! $ILLR $BTC.X $KITT $QNRX About to run !
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 5:34 PM
$QNRX 20k shares available borrow free 49 percent at
0 · Reply
Kevin73ca
Kevin73ca Jun. 26 at 3:09 PM
$CYN watch $QNRX this is also next
0 · Reply
prismmarketview
prismmarketview Jun. 26 at 2:37 PM
$QNRX “It’s not just a skin disease—it can be life-threatening.” Quoin Pharmaceuticals (Nasdaq: QNRX) spotlights the urgent pediatric need in Netherton Syndrome in a powerful new NETHERTON NOW episode featuring leading dermatologist Prof. Jemima Mellerio. Don’t miss this expert perspective on the fight to bring treatments to children who need them mosthttps://prismmarketview.com/quoin-pharmaceuticals-highlights-urgent-pediatric-need-in-netherton-syndrome-with-new-expert-video/
0 · Reply
StayPresent
StayPresent Jun. 25 at 11:18 PM
$QNRX should be OTC. China dog💩
1 · Reply
Yuyus
Yuyus Jun. 25 at 11:36 AM
$QNRX Quoin Pharmaceuticals Secures FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome June 24, 2025
0 · Reply
prismmarketview
prismmarketview Jun. 24 at 1:35 PM
$QNRX https://prismmarketview.com/quoin-pharmaceuticals-secures-fda-rare-pediatric-disease-designation-for-qrx003-in-netherton-syndrome/
0 · Reply
volatilelt
volatilelt Jun. 24 at 12:58 PM
$QNRX Let's have +50% day - thats about time have a payday for long time investors
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 24 at 12:41 PM
$QNRX (+13.1% pre) Quoin Pharmaceuticals Ltd (QNRX) Granted FDA Rare Pediatric Disease Designation for QRX003 https://ooc.bz/l/68433
0 · Reply
ShadowSnake
ShadowSnake Jun. 24 at 12:39 PM
$QNRX when $50!?
0 · Reply
Stmkr
Stmkr Jun. 18 at 4:48 AM
$AZTR $QNRX AZTR ✓ Next favorites; - $QNRX - $EVAX
0 · Reply
StayPresent
StayPresent Jun. 14 at 1:12 AM
$QNRX giant pos scam. This is OTC garbage without the RS.
0 · Reply
WhoDoneIt69
WhoDoneIt69 Jun. 13 at 3:26 PM
$QNRX There’s so much room to dilute!!!
0 · Reply
Tofer85
Tofer85 Jun. 11 at 8:50 PM
$JAGX $LYRA $PLRZ $QNRX $TAOP really 🤦‍♂️
0 · Reply
BreakoutBetter
BreakoutBetter Jun. 11 at 6:36 PM
$JAGX low float verging breakout $TAOP $LYRA $PLRZ $QNRX rs
0 · Reply
Stmkr
Stmkr Jun. 11 at 12:25 PM
$AZTR $QNRX Among the next penny stocks overdue for a spike
0 · Reply
ShadowSnake
ShadowSnake Jun. 9 at 12:51 PM
$RNAZ $QNRX They took $TNXP under $7 after their reverse split and look where they are now!!!
0 · Reply
ShadowSnake
ShadowSnake Jun. 7 at 10:22 PM
$QNRX I need this to move like $TNXP …
1 · Reply